Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14732452 | 0.88 | LMNA (0.64) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL19321970 | 0.87 | HTR7 (0.52) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL10323667 | 0.86 | TDP1 (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL20831009 | 0.86 | TDP1 (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL18427933 | 0.86 | KMT2A (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| Benzyl Benzoate SCHEMBL23455668 | 0.86 | TDP1 (0.68) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL20831010 | 0.86 | KMT2A (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL22580688 | 0.86 | RAB9A (0.50) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL20831011 | 0.86 | TDP1 (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL20831007 | 0.86 | TDP1 (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20120101236-A1 | POLYIMIDE PRECURSOR COMPOSITION CONTAINING POLYAMIC ACID ALKYL ESTER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | TDP1 2649/4885KMT2A 3832/4885SLC6A2 854/4885 |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | TDP1 2649/4885KMT2A 3832/4885SLC6A2 854/4885 |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | SNCA, PARK7, APP | TDP1 428/4885KMT2A 3139/4885SLC6A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.